NRXP NRx Pharmaceuticals, Inc.

NASDAQ
$2.55

NRx Pharmaceuticals, Inc. (NRXP) is expected to report earnings on February 15, 2027, before the market open. The consensus earnings estimate is a loss of $0.34 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +19.2% since its last earnings release on November 16, 2026.

NRx Pharmaceuticals Beat Consensus Estimates
Tuesday, November 17, 2026 · 7:18 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 15
Monday · Before Open
Earnings Whisper
-
vs ($0.34)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $2.65

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About NRx Pharmaceuticals, Inc.

NRX Pharmaceuticals Inc. is a patient-focused, clinical stage pharmaceutical company. It creates therapies to treat diseases where no medicines currently exist. NRX Pharmaceuticals Inc., formerly known as Big Rock Partners Acquisition Corp., is based in RADNOR, Pa.

Sector

Healthcare

Industry

Drug Manufacturers/Other

Charts powered in part by Lightweight Charts™ by TradingView.